{"id":"W2922249564","doi":"10.1182/blood-2019-01-896290","title":"Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Genentech; Cancer Research UK; F. Hoffmann-La Roche","keywords":"Venetoclax; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Refractory (planetary science); Fludarabine; Leukemia; Bendamustine; Ibrutinib; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00138605,0.0009134733,0.001334507,0.0002949341,0.000376823,0.0006298675,0.0006185327,0.0007567998,0.001935535],"category_scores_gemma":[0.000595074,0.0003601408,0.0004670951,0.0003122682,0.000566906,0.0004400025,0.0001825831,0.001842248,0.0004041943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005958328,"about_ca_system_score_gemma":0.001090892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00106015,"about_ca_topic_score_gemma":0.002571395,"domain_scores_codex":[0.999713,0.0001512938,0.00001151151,0.00004289382,0.00002593269,0.00005519365],"domain_scores_gemma":[0.9995932,0.00008275647,0.00008794598,0.00003285035,0.00002423102,0.0001791197],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4618611,0.127332,0.01277621,0.001223374,0.0008477739,0.0007925442,0.0005216378,0.004353665,0.2170849,0.0004845733,0.004610386,0.1681119],"study_design_scores_gemma":[0.3348839,0.6239694,0.02117461,0.00007401173,0.0002485269,0.0007201145,0.00006608989,0.002002403,0.01232338,0.0001523748,0.004353291,0.00003191254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959365,0.001939071,0.0002846384,0.0001250654,0.00005121451,0.0006683445,0.0002718744,0.00004515206,0.0006781899],"genre_scores_gemma":[0.9940128,0.001545456,0.00101361,0.0002570296,0.000104773,0.0006871909,0.0008628899,0.00001475474,0.001501554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001935535,"threshold_uncertainty_score":0.007330179,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01331729804762806,"score_gpt":0.29284353042943,"score_spread":0.2795262323818019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}